MK0767 and Sulfonylurea Combination Study (0767-027)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00543491

Enrollment

129

Registered

2007-10-15

Start date

2003-05-31

Completion date

2003-12-31

Last updated

2015-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Interventions

DRUGMK0767

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to 78 Years

Healthy volunteers

Inclusion criteria

* Type 2 Diabetes with inadequate glycemic control * On Sulfonylurea monotherapy * Male or non-pregnant Females * Age 21 to 78 years, inclusive * On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week-6

Exclusion criteria

* History of Type 1 diabetes * Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPAR-y agonists, Metformin agents * Patients with history of or intolerance of PPAR-y agonists

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026